#News for #Media and #Investors: The FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs). With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives. Learn more: gsk.to/4aBCpje

#News for #Investors and #Media: Today, we announced that the US FDA and the EMA have granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome. Learn more: gsk.to/4vJGgCT

#News for #investors and #media: Following today’s agreement to acquire Nuvalent, Inc., our CEO Luke Miels shares why this acquisition is strategically important to our oncology business as we continue to strengthen our pipeline and commitment to patients. Read more from Luke in our press release: gsk.to/4gaudKr

#News for #investors and #media: We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/4ooHOjy

#News for #investors & #media: Today at #EASLCongress, we’re presenting results from a phase III trial in chronic hepatitis B, a disease affecting approximately 240 million people globally. Thank you to everyone involved who made this research possible. 🔗 Learn more: gsk.to/3Q8X47g

#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/4wPL9f1

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: gsk.to/3PKzP3i

At #ATS2026, we're sharing findings from 33 research projects across our portfolio of inhaled therapies and biologics – reflecting our ambitious treatment goals, moving beyond symptom control to transform outcomes for people living with chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Our innovation is driving new treatment approaches including long-acting therapies, which aim to redefine care and alleviate the significant burden on patients and health systems worldwide. We believe advancing research is one of the most meaningful investments we can make for a healthier future.

#News for #investors and #media: At #ATS2026, we’ll be presenting data across 33 abstracts to highlight our research as we work to redefine respiratory care. gsk.to/42ejQxd

News for #Investors and #Media Explore the key highlights from our Q1 2026 results announcement ⤵️ Find out more: gsk.to/4uelV7Y $GSK

#Investors: Join GSK’s CEO Luke Miels and other members of our leadership team for our Q1 2026 results webcast at 12:00 BST, 07:00 EST. $GSK

We’re announcing our Q1 2026 results tomorrow at 07:00 BST, 02:00 EST. $GSK

#News for #investors and #media: Today we are announcing that our potential first-in-class treatment for chronic hepatitis B has been accepted for regulatory review by the US FDA. It has also received Breakthrough Therapy designation. 🔗 Learn more: gsk.to/4tG7JoC

#News for #investors and #media: Today we announced that our investigational liver therapy received US FDA Breakthrough Therapy and EMA Priority Medicine (PRIME) regulatory designations for metabolic dysfunction-associated steatohepatitis (MASH). Find out more: gsk.to/4cBwMDm

#News for #Investors and #Media China’s National Medical Products Administration (NMPA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: gsk.to/3QbmAsq

#News for #investors and #media: Today we announced the completion of our acquisition of 35Pharma Inc., adding to our Respiratory, Immunology & Inflammation pipeline. Find out more: gsk.to/4cslO1G

#News for #Investors and #Media: Today at #SGO2026, we’re presenting new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: gsk.to/4c4OqPv

#News for #Media and #Investors: China's National Medical Products Administration (NMPA) has approved our new therapy for people living with chronic rhinosinusitis with nasal polyps (CRSwNP). For more information, visit: bit.ly/43sHkQ0